The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Be interesting to see if he clears his name, in the shirt time I've seen SRT mentioned he seems to over promise and under deliver
This almost describes perfectly PYC target market
With the increasing investigation of DNA damage response / PARP inhibitors, alone or in combination with chemotherapy or immunotherapy, there is a need for minimally invasive, robust and repeatable DDR assays. All the development work continues to add to the menu of assays owned by ANGLE that we can offer to other customers."
The DDR therapeutics market was estimated to be valued at US$5.9 billion in 2022 and is projected to reach US$10.4 billion by 2031 with a CAGR of 6.5%1. This is expected to be driven by an increase in the use of combination therapy for the treatment of drug-resistant cancers and the need for novel targeted medicines for cancer treatment. Most cancers rely on the DDR pathway to a greater extent than healthy cells. Treating patients with a DDR inhibitor alongside another cancer drug helps to maximise DNA damage and selectively kill cancer cells. This provides a targeted approach to cancer treatment with the potential to improve patient outcomes across multiple tumour types.
Interesting developments at fellow bio tech AGL
Could well be PYC next to form this type of partnership? (Alongsode our work with merck)
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology has signed a supplier agreement with the global biopharmaceutical company, AstraZeneca PLC, to develop and validate a methodology leveraging ANGLE's existing DNA damage response ("DDR") assay for the detection of micronuclei in CTCs as a measure of DDR
Yes Mark
The price is due to breakout this week amd this has been coupled with block buying all week ...
There has been NO holdings RNSs ďeapite 60% institutional holdings
In fact only one since Feb has been a USA fund increasing
Yes
If you look at the psots from 2 weeks ago 12-15p was initially target
RQIH 10p+ (cureent 3p)
PYC 5p+ (current 1.5p)
SAR now 230% up from purchases
Well done Mr calm
You'll like the other 2 also ( rqih and pyc)
Well done Mr calm
You'll like the other 2 also ( rqih and pyc)
Due to the low free-float thin-will move quickly
RQIH and PYC have identical charts to what SND had at 3.3p
Was buying SND at 3 2p/3 3p and now nearly 40% up with more left to go up
10p has always been the bare minumun (see previous posts)
RQIH 3p and worth 40p!! On asset sale
SAR up 200% since i bought at 10p
SND RQIH PYC the next 3 big movers
We flagged this up at 3 2p 2 weeks ago
It's looking good now
Thanks to Smartmoney and scorcer etc
Last update
On the basis set out in the circular sent to shareholders on 14 December 2023 and in recent announcements, R&Q continues to work expeditiously towards achieving satisfaction of the conditions to enable that sale to take place.
R&Q continues to expect closing of that sale to occur in Q2 2024.